Optic Neuropathy in Idiopathic Intracranial Hypertension

Corina Merticariu¹, Florian Balta², Mircea Merticariu³, Ramona Barac⁴, Liliana Voinea⁵

¹Victor Gomoiu Pediatric Hospital, Bucharest, Romania
²Vitreo-retinal Department, Emergency Eye Hospital and Clinic, Bucharest, Romania
³Carol Davila Nephrology Hospital, Bucharest, Romania
⁴Department of Ophthalmology, Emergency Eye Hospital and Clinic, Bucharest, Romania
⁵University Emergency Hospital, Bucharest, Romania

ABSTRACT

Adult patients who present with papilloedema and symptoms of raised intracranial pressure need urgent multidisciplinary assessment including neuroimaging, to exclude life-threatening causes. Where there is no apparent underlying cause for the raised intracranial pressure, patients are considered to have idiopathic intracranial hypertension (IIH).

Objectives: This review encompasses the newly revised diagnostic criteria for PTCS in adults and children and the role of obesity in the epidemiology, etiology, and management of IIH. Furthermore, this paper tries to offer a practical approach to assessing patients with papilloedema, the investigations and the subsequent management of patients with IIH.

Methodology: PubMed was used to search for IIH and Pseudotumor Cerebri. The vast majority of the literature consisted of cohort studies, case control studies, systematic reviews and other narrative reviews.

Conclusion: Idiopathic intracranial hypertension (IIH), also known as primary Pseudotumor Cerebri syndrome (PTCS), is a condition of unknown etiology which affects primarily overweight, reproductive-aged women and causes increased intracranial pressure (ICP). This review discusses the recently revised diagnostic criteria for IIH for adults and children and the controversial issues in its diagnosis and management.

Key words: idiopathic intracranial hypertension, acetazolamide, pseudotumorcerebri

INTRODUCTION

Once thought to be rare, IIH is becoming more common with an estimated incidence of 15-19 cases per 100,000 among overweight or obese women ages 20-44. (1) This increasing incidence has been attributed to the growing obesity epidemic among adults. It most often affects obese or overweight adult females and can lead to blindness in up to 10% of patients, particularly if it is not recognized or treated promptly. (2)
Epidemiology

Idiopathic intracranial hypertension (IIH) is a disease that has a significant burden on the individual and on society. On average, the incidence of IIH in the general population is 0.5-1.0/100,000 (3) and 3.5 / 100,000 in young women aged 20 to 44. (4)

The pathogenic mechanism underlying it is unknown and there is no sign of cerebral edema. Obesity is a major risk factor, as the incidence of IIH is 13 / 100,000 in women with >10% over their optimal body mass index (BMI) and 19 / 100,000 in women with >20% % over their optimal body mass index (BMI). Moreso, 86% of patients with IIH are obese and 12% overweight. Although it is mostly described as a disease affecting young overweight women, there is an increasing incidence in overweight men and children, parallel to the rising prevalence of obesity. (1,5,6,7)

In Romania, according to the latest statistics, 19.1% of the women aged 18 to 44 years are overweight, which is more than twice the value reported in 1980 when the rate of obesity in the general population was only 8.6%. (8)

Pathogenesis

The pathogenesis of IIH is unknown. Although brain edema, increased cerebral blood volume, and increased CSF secretion have been postulated as IIH mechanisms (9) most attention has been focused on increased venous sinus pressure and decreased CSF absorption. Decreased CSF absorption by arachnoid villi has been demonstrated by radioisotope cisternography, although it is unclear whether it is secondary to compression of the arachnoid villi or by elevated ICP itself. (10)

Diagnosis

Idiopathic intracranial hypertension (IIH) is a disorder that typically presents with headache and blurred vision and is diagnosed by the presence of papilledema and elevated intracranial pressure in the absence of infectious, vascular, or structural causes. Patients with IIH have normal levels of consciousness and functioning. (11)

Patients who present with papilledema and symptoms of raised intracranial pressure need urgent multidisciplinary assessment including neuroimaging, to rule out life threatening conditions. Where there is no apparent underlying cause for the raised intracranial pressure, patients are considered to have idiopathic intracranial hypertension (IIH). (12)

At the moment IIH is confirmed, up to 90% of patients already have various degrees of visual impairment and 10 to 24 % finally progress to permanent severe visual impairment. Visual loss can occur any time along the course of the disease and is usually insidious. Central vision is not affected until late so the visual loss is usually unnoticed by the patient, up to when it is very advanced.

Furthermore, the diagnosis is usually delayed as medical knowledge about IIH is scarce and many doctors from different clinical subspecialties are consulted before the patient is finally diagnosed and treated. Visual prognosis depends on the speed of diagnosis and on a thorough follow-up.

As the vast majority of patients with IIH complain of impairing headaches, therapeutic attitude towards IIH varies. Although it is the only irreversible damage of the disease, visual loss usually occurs gradually and silently, only a small percent of patients having a high risk of rapid visual loss.

Visual acuity loss in IIH can be caused by both outer retinal changes and optic neuropathy. Retinal changes include chorioretinal folds, hyperopic shift, hemorrhages, macular edema, subretinal fluid, or, rarely, subretinal neovascularization. (13)

Distinguishing outer retinal changes from optic neuropathy as the cause of decreased visual acuity is important, because outer retinal changes in the macula affecting visual acuity may be largely reversible, whereas fulminant IIH with optic neuropathy and neuronal loss may require more aggressive management, such as immediate surgical intervention, to prevent further vision loss and irreversible blindness. (14,15,16,17,18)

Diagnostic criteria for adult IIH- Adapted from the 2013 revised diagnostic criteria for IIH: (19)

- Papilledema;
- Normal neurological examination except for cranial nerve abnormalities;
- Neuroimaging: Normal brain parenchyma without hydrocephalus, mass or structural lesion and no abnormal meningeal enhancement or venous sinus thrombosis on MRI and MR venography; if MRI is unavailable or contraindicated, contrast-enhanced CT may be used;
- Normal CSF composition;
- Elevated CSF opening pressure (≥25 cm H2O) in a properly performed lumbar puncture.

A diagnosis of IIH is definite in patients fulfilling A–E; the diagnosis is probable if A–D are met but the CSF pressure is lower than specified.

The diagnosis can be difficult and the consequences of error can lead either to the neglect of a serious treatable cause of raised intracranial pressure, blind-
ness or inappropriate treatment of patients who do not have IIH. Although there is insufficient literature to generate an evidence-based management strategy for IIH, experienced clinicians can manage it well. (20) (fig. 1)

**Papilloedema**

Patients generally present to the emergency department after an optometrist or family doctor detects papilloedema. They may or may not have other symptoms. Because papilloedema indicates potentially serious underlying disease, the purpose of the visit is to recognise and confirm the presence of papilloedema and arrange appropriate onward investigations. (12)

When there is papilloedema with symptoms and signs of raised intracranial pressure, it is important to obtain a thorough past history and system screen to identify treatable causes:

- Secondary causes of raised intracranial pressure for exclusion to diagnose IIH:
  - Venous sinus thrombosis;
  - Anaemia;
  - Obstructive sleep apnoea;
  - Drug-related;
  - CSF hyperproteinaemia/hypercellularity, for example, spinal cord tumour / meningitis / Guillain-Barré syndrome/subarachnoid haemorrhage;
  - Renal failure;
  - Endocrine diseases, for example, Addison’s/Cushing’s/hypothyroidism;
  - Drugs associated with pseudotumour cerebri: (12)
    - Tetracycline/minocycline/doxycycline;
    - Corticosteroids;
    - Beclometasone;
    - Nitrofurantoin;
    - Tamoxifen;
    - Sulphonamides, for example, trimethoprim;
    - Ciclosporin;
    - Nalidixic acid;
    - Non-steroidal anti-inflammatory drugs;
    - Vitamin A excess and retinoids;
    - Cimetidine;
    - Lithium;
    - Depo Provera.

**Neuroimaging**

Having identified papilloedema, it is essential to record blood pressure to exclude malignant hypertension. Patients then need urgent neuroimaging: this has two purposes, to identify any space-occupying lesion and to exclude a venous sinus thrombosis. The preferred imaging method is an MR scan of the head and orbits with intravenous contrast and MR venogram; these should, ideally, include fat suppression sequences, as these better define the intraorbital optic
nerves. However, if this is not readily available, a CT head scan with a CT venogram will exclude most space-occupying lesions, cerebral venous sinus thrombosis and Chiari malformation. There are several possible radiological signs of IIH, although none is pathognomonic. There may be an empty sella, a partially empty sella, decreased pituitary height or transverse sinus narrowing. In the orbits, the optic nerve sheath complex may be enlarged, the posterior globe flattened and occasionally the optic nerve head protruded. (21)

**Lumbar puncture**

After excluding a structural intracranial lesion, patients require a lumbar puncture, performed with the patient in the lateral decubitus position. Whiteley’s clinical study found the normal range for lumbar CSF opening pressure was 10-25 cm CSF (95% reference interval); but some normal subjects had opening pressures of up to 28 cm CSF. (22) In adults and children the assessment of average CSF pressure over more than 20 minutes, ‘steady state’, is reported to be more reliable than a single opening pressure measurement using the height of a fluid column. (23,24,25)

Diagnostic errors resulted in overdiagnosis of IIH in 39.5% of patients referred for presumed IIH to a neuro-ophthalmology service of a tertiary center and prompted unnecessary tests, invasive procedures, and missed diagnoses. The most common errors were inaccurate ophthalmoscopic examination in headache patients and thinking biases, reinforcing the need for rapid access to specialists with experience in diagnosing optic nerve disorders. Indeed, the high prevalence of primary benign headaches and obesity in young women often leads to costly and invasive evaluations for presumed IIH. (26)

As emphasized in the DEER (diagnostic error evaluation research) classification, diagnostic errors can result from various mistakes along the course of a patient evaluation. Most errors resulted from inability to perform an accurate physical examination (i.e., ocular fundus examination) and from the difficulty in deviating from a previously suspected diagnosis (based on the intuitive presumption that obese women with headaches must have IIH). In a few cases, isolated radiologic findings raised a concern for IIH, or moderately elevated CSF opening pressure in the absence of papilledema or sixth nerve palsies prompted the wrong diagnosis. (26)

There are a number of relatively simple ways to reduce the risk of misdiagnosis.

Studies suggest that characteristic MRI findings include empty sella turcica, decreased pituitary gland size, optic nerve tortuosity, perioptic subarachnoid space enlargement, posterior globe flattening, and intracranial protrusion of the optic nerve head. In these patients, a detailed fundoscopic examination by an experienced ophthalmologist or neuro-ophthalmologist, should be enough to either confirm papilloedema and lead to further investigations, or refute it and render other investigations useless. (27)

Apart from this, recent findings suggest that on optical coherence tomography (OCT), increased retinal nerve fiber layer and macular thickness may be observed in children with IIH compared with controls. The retinal nerve fiber layer thickness seems to coincide with the severity of papilledema and may be more sensitive than fundoscopy for detecting optic nerve head elevation. (fig. 2) (28) Research on ultrasound of the optic nerve shows increased size of the

![Figure 2 - Optical coherence tomography (cross-sectional image) through an optic disc with drusen and papilloedema](http://example.com/figure2a.png)

(a) Optical coherence tomogram (cross-sectional image) through an optic disc with drusen showing the typically irregular tissue underlying the elevated surface of the disc with no extension of the sub-retinal hyporeffective layer (arrows) beyond the optic nerve head; (b) Optical coherence tomogram (cross-sectional image) of a papilloedematous optic disc showing a smoothly elevated disc with underlying hyporeffective fluid extending beyond the disc into the sub-retinal space in a ‘lazy V pattern’ (illustrated by lines) [adapted from Choi SS et al (28)]
optic nerve sheath diameter in pediatric IIH patients, and this may correlate with increased opening pressure on lumbar puncture. (29)

Other investigations

Patients in whom the intracranial hypertension is not truly idiopathic but has an identifiable etiology (otitis media, dural sinus thrombosis, systemic lupus erythematosus, neck injury, metastatic disease, nephrotic syndrome or arteriovenous malformations) should be excluded.

Evolution of optic neuropathy in IIH

Disease evolution and outcomes in IIH are poorly characterised and are currently being evaluated in the National IIH: LIFE study. The following patient types were noted: (12)

- Those who rapidly lose vision at diagnosis over days to weeks (rare but vital to identify early);
- Those whose disease resolves following diagnosis, over weeks to months, occasionally after a single lumbar puncture (rare);
- Those at lower risk of visual loss who develop chronic disease with small fluctuations in disease activity, frequently with weight changes (the majority);
- Those in disease remission and off treatment.

Diagnosing and monitoring optic neuropathy in IIH is the clinical priority for all patients. Visual function can be fully assessed only by measuring visual acuity, colour vision and visual field testing. Pupillary reflex tests and slit-lamp examination should be performed by an experienced ophthalmologist or a neuroophthalmologist. According to recent studies and improvement in available software, optical coherence tomography (OCT) is proving to be useful in aiding the diagnosis and follow-up of papilledema and optic neuropathy. (table 1)

Treatment and management

Different treatment options are available. Conservative measures focus on weight loss, either through diet or through bariatric surgery. Pharmacological therapy includes diuretics. Surgery is reserved for cases reluctant to medical treatment and involve optical nerve fenestration, CSF divergence and venous sinus stenting. It should only be advised in cases with malignant intracranial hypertension or rapid progression, if there is severe sight threatening. Surgical treatment did not prove effective in alleviating headaches. (30) According to symptom severity, the majority of doctors use a stratified treatment strategy for idiopathic intracranial hypertension. (fig. 3) Proposal of a stratified treatment strategy for idiopathic intracranial hypertension according to symptom severity. (31)

Management of acute visual loss in IIH

In high-risk patients with impending visual loss, some form of CSF divergence can be sight-saving and can sometimes lead to visual recovery. Options include a ventriculoperitoneal, lumboperitoneal shunt, where a catheter is inserted into the subarachnoid space either in the lateral ventricles or at the lumbar spine between two vertebrae and fed around the oblique muscles under the skin into the peritoneum. Less commonly, a ventriculoatrial or a ventriculopleural shunt can divert CSF from the lateral ventricle to the atrium or the pleura. (32) While the shunt is working, weight reduction is advised, to put their disease into remission. Additionally, shunting exclusively to treat headache, is almost never recommend as this continues in most patients postoperatively (68% at 6 months and 79% at 2 years). Also, postoperative low-pressure headache occurs in 28%. Although shunting seems effective in alleviating acute symptoms of IIH, significant complications include blockage of drainage,
infections, intracranial low-pressure, chronic abdominal and back pain. Moreso, over half the patients need shunt revision, and one-third need multiple revisions. (32) Optic nerve sheath fenestration is an alternative for protecting the vision; however, it has little effect on the overall intracranial pressure and can lead to visual loss in inexperienced hands. In situations of acute, severe visual loss, the combination of oral or IV acetazolamide and IV methylprednisolone 15 mg/kg can be used when surgery is not immediately available. (33)

**Pharmacological management**

Carbonic anhydrase inhibitors, such as acetazolamide, can provide symptomatic relief of raised intracranial pressure, although there is no evidence to support their long term benefit. The maximum dose is up to 2 g/daily; usually, up to 1 g daily is adequate, depending on body weight. Common dose-related side effects include GI upset, paresthesias involving the lips, fingers, and toes, anorexia, and electrolyte imbalance (metabolic acidosis). When the side effects become intolerable, the dose is lowered or acetazolamide is replaced or combined with furosemide. Topiramate, an antiepileptic medication which has secondary carbonic anhydrase activity, may be used as a second-line agent. Topiramate use in IIH is relatively new and has the added benefit of appetite suppression and weight loss in many patients. It is an excellent medication for chronic daily headache and has been used safely for years in patients with epilepsy. Although the optimal duration of treatment is unknown, some experts recommend that treatment is continued for at least 6 months after visual status, and optic nerve appearance stabilize before tapering off medications. (34)

Studies so far, could neither support nor deny the longterm benefit of acetazolamide or any other type of medical therapy in the treatment of IIH. (35,36)

**Conservative management**

Weight loss is currently the only proven disease-modifying treatment for all overweight patients. Recent studies highlighted that a 15% reduction of body weight, using a low calorie meal replacement liquid diet for 3 months, significantly reduced intracranial pressure, papilloedema and headaches. (37,38) Furthermore, current studies suggest that bariatric surgery might have an important role in the long-term treatment of IIH. (39,40)

**CONCLUSION**

Idiopathic intracranial hypertension is associated with severe morbidity due to the associated optic neuropathy and severe headaches. This review summarizes the relevant articles on the diagnostic tools used in evaluation management of IIH, highlighting the importance of early recognition and management of optic neuropathy to prevent permanent visual loss.

Steady state CSF pressure assessment, rather than measuring CSF opening pressure as well as expert opinion on high-quality MRI and MRV is often helpful. Before subjecting a patient to invasive investigations, on the basis of possible papilloedema, it is recommended that he be examined by an expert ophthalmologist, also using ultrasonic and OCT imaging to support the diagnosis.

By organizing a functional pathway and easy access to medical visits and follow-up, diagnosis can be effectively carried out by a team of professionals comprising an ophthalmologist, a neurologist, a radiologist and a nutritionist and treatment can be adjusted according to individual needs. Therefore, raising awareness and further research into how to diagnose and treat IIH is of the utmost importance.